- Chairman of the National Council for the Prevention, Diagnosis and Treatment of Cancer in Israel.
- He uses the latest drugs for the treatment of various forms of cancer, actively participates in the development of methods of personalized medicine.
- Author of more than 120 scientific publications.
Ido Wolf’s research addresses a wide range of issues related to oncology, including molecular mechanisms and clinical aspects. Several key areas can be distinguished in his work:
- Oncology and COVID-19: Several articles explore the specifics of oncology practice and treatment of cancer patients during the COVID-19 pandemic, including the impact of the virus on disease course, the efficacy of vaccination, and the use of telemedicine in the challenging pandemic environment.
- Personalized Therapies and Biomarkers: Wolf is actively studying molecular markers, such as the hormone Klotho, to develop personalized therapies and predict outcomes in breast cancer and other cancers. For example, his work shows how lower levels of Klotho in the blood are associated with more aggressive forms of tumors.
- Oncogenesis and Genetic Mechanisms: Wolf’s research examines genetic mutations and mechanisms that affect the resistance of tumors to therapy. For example, mutations in estrogen receptors are associated with treatment resistance in hormone-dependent breast cancer.
- Emerging Technologies in Oncology: Several publications discuss innovative approaches, including artificial intelligence and data analytics, to improve diagnosis and the selection of therapeutic regimens, especially in the treatment of lung cancer.
- Immunotherapy and side effects: Wolf’s research includes work on side effects of immunotherapy, such as cardiotoxicity, and the effects of drugs and complementary agents such as medical cannabis on tumor treatment.